Recombinant Human CD79B/CD79β Protein (C-His)

Measured by functional ELISA. Immobilized recombinant human CD79B binds polatuzumab vedotin-derived reference antibody with an EC50 in the range of 10–50 ng/mL.

CD79B (Igβ, B29) is the signaling subunit of the B-cell receptor: paired with CD79A, it associates with surface immunoglobulin and delivers activation signals through its cytoplasmic ITAM motifs. Because CD79B is expressed across the B-cell lineage — including malignant B cells that may lose surface immunoglobulin expression — and is efficiently internalized upon antibody binding, it has become a premier target for antibody–drug conjugates in lymphoma. Polatuzumab vedotin established the target clinically in diffuse large B-cell lymphoma, and next-generation CD79B ADCs and bispecifics are advancing rapidly. The extracellular Ig-like domain presented here is the epitope-bearing region accessible to therapeutic antibodies, supporting ADC screening, affinity maturation and potency assay development for the growing CD79B pipeline.